CD80/CD86 Blockade and T-Cell Dynamics

How does CD80/CD86 blockade by abatacept affect T-cell activation and tolerance?

Abstract

CD80/CD86 blockade by abatacept consistently reduces T-cell activation across multiple disease contexts through selective modulation of CD28-mediated costimulation. Treatment decreases expression of activation markers (CD38, ICOS, Ki-67) and reduces proliferation particularly in CD4+ T cells, with 7-10-fold fewer proliferating and activated effector memory CD4+ T cells observed in GVHD prevention. Abatacept shifts CD4+ compartments toward naive phenotypes while reducing central memory populations, with transcriptional analysis revealing decreased expression of genes regulating cell cycle and chromatin dynamics. CD8+ T-cell subsets remain relatively resistant to these effects, indicating lesser reliance on CD28 costimulation. The effects are reversible after treatment discontinuation, with T-cell populations returning to baseline within 6 months, indicating that abatacept maintains an altered immune state through continuous pharmacological inhibition rather than inducing permanent tolerance.

Effects on regulatory T cells are context-dependent and paradoxical: in rheumatoid arthritis, abatacept increases Treg numbers through reduced apoptosis but diminishes their suppressive function because CD80/CD86 blockade on responder T cells reduces susceptibility to Treg-mediated suppression. In multiple sclerosis, memory Treg frequencies decrease due to their dependence on ongoing costimulation. Clinical translation of these immunological effects varies substantially by disease, with robust benefits observed in GVHD prevention where transient early suppression of donor T-cell activation is sufficient, sustained benefits in established rheumatoid arthritis with high baseline T-cell activation, but no clinical improvement in mild atopic asthma despite similar shifts in T-cell populations. This heterogeneity suggests that costimulation blockade is most effective when CD28-dependent T-cell responses drive disease pathology and baseline immune activation is high.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question. More on methods.

Records from Elicit search

• n = 200

Papers screened using:

• Abatacept Intervention,

• T-cell Outcomes,

• Control Groups,

• Study Design,

• Intervention Isolation,

• Study Setting,

• Publication Status,

• Intervention Specificity

• n = 200 Papers screened out

• n = 190 Papers included for extraction

• n = 10

Screening

We screened in sources based on their abstracts that met these criteria:

• Abatacept Intervention: Does this study investigate abatacept as the primary intervention?
• T-cell Outcomes: Does this study measure T-cell activation markers (e.g., CD25, CD69, cytokine production, proliferation assays) or T-cell tolerance outcomes (e.g., regulatory T-cell function, anergy markers, immune suppression indicators)?
• Control Groups: Does this study include appropriate comparison groups (placebo, standard care, or pre-treatment baseline)?
• Study Design: Is this study a randomized controlled trial, controlled clinical trial, or systematic review/meta-analysis?
• Intervention Isolation: Can the effects of abatacept be isolated from other interventions in this study?
• Study Setting: Is this a human or animal study with in vivo or clinical correlation (not purely in vitro)?
• Publication Status: Is this a peer-reviewed, published study with complete methodological details (not a conference abstract or unpublished study)?
• Intervention Specificity: Does this study focus on abatacept rather than other CD80/CD86 blocking agents without abatacept?

We considered all screening questions together and made a holistic judgement about whether to screen in each paper.

Data Extraction

We asked a large language model to extract each data column below from each paper.

• Study Model: Extract the disease model or clinical context used to study CD80/CD86 blockade effects on T-cells.
• Abatacept Regimen: Extract specific details about abatacept treatment for CD80/CD86 blockade.
• T-cell Activation Measures: Extract how T-cell activation was assessed and the specific findings related to CD80/CD86 blockade by abatacept.
• T-cell Tolerance Measures: Extract how T-cell tolerance or regulatory function was assessed and the specific findings related to CD80/CD86 blockade by abatacept.
• T-cell Subset Effects: Extract the specific T-cell populations affected by CD80/CD86 blockade and the direction/magnitude of effects.
• Mechanistic Insights: Extract molecular and pathway-level insights into how CD80/CD86 blockade by abatacept affects T-cell activation and tolerance.
• Effect Kinetics: Extract the temporal pattern of T-cell activation and tolerance changes following CD80/CD86 blockade.
• Study Limitations: Extract factors that could affect interpretation of T-cell activation and tolerance effects from CD80/CD86 blockade.

Results

Characteristics of Included Studies

The included studies examined abatacept’s effects across diverse autoimmune and transplant contexts. Five studies had full text available. Disease models included rheumatoid arthritis (4 studies), type 1 diabetes (2 studies), GVHD prevention (2 studies), multiple sclerosis (1 study), and asthma (1 study). Most studies used approximately 10 mg/kg dosing at 4-week intervals, though treatment durations varied from 3 months to 24 months. Concomitant immunosuppression was common, including methotrexate in rheumatoid arthritis studies and calcineurin inhibitors plus methotrexate in GVHD prevention studies.

Effects on T-cell Activation

Activation Marker Expression

Abatacept treatment reduced expression of multiple T-cell activation markers across disease contexts. In GVHD prevention, CD4+ T cells showed 7-fold fewer proliferating cells (Ki-67+) and 10-fold fewer activated cells (CD38+/HLA-DR+) at day +28 compared to controls, with effects concentrated in effector memory populations. In multiple sclerosis, abatacept decreased the proportion of CD38+ and ICOS+ activated cells within both T follicular helper (Tfh) and regulatory T cell populations. Rheumatoid arthritis patients exhibited downregulation of activation-associated markers and CD95 on CD4+ T cells and Tregs.

The activation changes were selective for certain T-cell populations. CD4+ T cells were consistently more affected than CD8+ T cells across studies. In type 1 diabetes, CD4+ conventional and regulatory subsets showed altered frequencies while CD8+ subsets remained relatively resistant, indicating lesser reliance on CD28-mediated costimulation in CD8+ cells. This differential sensitivity extended to specialized subsets, with Tfh cells showing progressive frequency declines and reduced activation marker expression in multiple sclerosis patients.

Proliferation and Cell Cycle Effects

Transcriptional analysis revealed that abatacept disrupted cell cycle and proliferation pathways in activated T cells. In multiple sclerosis patients, abatacept reduced expression of genes regulating cell cycle and chromatin dynamics during cell proliferation, directly linking reduced costimulatory signaling to impaired activation and proliferation. This was consistent with functional proliferation measures showing significant inhibition of CD4+ T cell proliferation in GVHD prevention, affecting both effector and central memory subsets.

Inflammatory Biomarkers

Beyond cellular activation markers, abatacept reduced soluble inflammatory mediators associated with T-cell activation. In rheumatoid arthritis, 12 months of treatment significantly decreased serum levels of IL-6, soluble IL-2 receptor, C-reactive protein, soluble E-selectin, and soluble ICAM-1 compared to placebo. Smaller reductions in TNF-α and rheumatoid factor were also observed. These systemic changes reflected the anti-inflammatory and immunomodulatory effects of selective CD28 costimulation blockade.

Effects on T-cell Subset Distribution

Abatacept consistently shifted CD4+ T-cell compartments toward naive phenotypes while reducing memory populations. In type 1 diabetes, abatacept treatment significantly reduced central memory CD4+ T cells (CD45RO+CD62L+) while increasing naive CD4+ T cells (CD45RO-CD62L+), with the reduction driven by decreased absolute numbers in circulation. The ratio of naive to central memory cells increased significantly throughout 24 months of treatment. Similarly, asthma patients showed increased naive and decreased memory CD4+ T cells after 3 months.

Within memory populations, effects were selective. Multiple sclerosis patients showed specific decreases in CD45RO+ memory Tregs while CD45RA+ naive Tregs remained unaffected. Tfh cells, a specialized memory subset, decreased progressively in frequency with accompanying reductions in activated (CD38+/ICOS+) Tfh cells.

Effects on Regulatory T Cells and Tolerance

Abatacept’s effects on regulatory T cells varied by subset and assay. In rheumatoid arthritis, total Treg numbers increased after treatment initiation, but functional suppression assays revealed diminished capacity to suppress responder T-cell proliferation. This occurred because CD80/CD86 blockade on responder T cells reduced their susceptibility to Treg-mediated suppression.

Multiple sclerosis patients exhibited decreased Treg frequency, particularly affecting memory Tregs expressing CD38 and ICOS activation markers. The demethylation status of the TSDR region in the FOXP3 gene also decreased, suggesting reduction in bona fide stable Tregs. In GVHD prevention, CD4+CD25high/CD127low/FoxP3+ putative Tregs transiently decreased in the abatacept cohort early after transplantation compared to standard treatment.

Type 1 diabetes studies showed trends toward reduced CD4+CD25high cells (enriched for thymus-derived Tregs), though associations with disease progression were not statistically significant. The reduction in central memory CD4+ T cells, which can differentiate into effector cells upon activation, accompanied by increased naive cells, represented a shift toward less activated immune states potentially favoring tolerance.

Temporal Dynamics of Effects

The onset and kinetics of T-cell effects varied by subset. In GVHD prevention, significant inhibition of CD4+ T-cell proliferation and activation was evident by day +28, but similar levels of activation were observed in treated and control cohorts after day +100, indicating transient effects limited to the period of drug exposure. The terminal half-life of abatacept (approximately 19.5 days) influenced the duration of immunological effects.

Type 1 diabetes studies demonstrated sustained effects during continuous treatment. Significant changes in central memory and naive CD4+ T cells were observed at 6, 12, and 24 months, persisting throughout the treatment period but returning to baseline values 6 months after treatment discontinuation. This reversibility was consistent across disease contexts, with multiple sclerosis patients showing complete reversal of cellular and molecular changes upon abatacept cessation.

Notably, different T-cell subsets exhibited distinct kinetic patterns. In multiple sclerosis, Treg frequency changes occurred as early as 4 weeks post-treatment while Tfh cell declines were observed later at 16 weeks, suggesting differential susceptibility to costimulation blockade across subsets.

Mechanistic Insights into Activation vs. Tolerance

Abatacept’s mechanism extends beyond simple CD80/CD86 blockade to affect multiple cellular processes. Transcriptional profiling in multiple sclerosis revealed that abatacept decreased expression of genes regulating cell cycle and chromatin dynamics during proliferation, directly linking reduced costimulatory signaling to impaired activation and cell division. The selective decrease in activated (CD38+/ICOS+) Tfh and Treg cells indicated that abatacept preferentially affected cells requiring ongoing costimulation.

The differential impact on CD4+ versus CD8+ T cells reflects their relative dependence on CD28 costimulation. CD8+ T-cell subsets showed resistance to abatacept effects in type 1 diabetes, suggesting lesser reliance on the CD28 pathway for activation and maintenance. This mechanistic distinction has important implications for which immune responses are modulated by costimulation blockade.

Rheumatoid arthritis studies revealed an additional mechanism: abatacept reduced CD95-mediated T-cell apoptosis in a dose-dependent manner, leading to increased T-cell numbers including Tregs. However, blockade of CD80/CD86 on responder T cells simultaneously diminished their susceptibility to Treg-mediated suppression, creating a paradox where Treg numbers increased but functional suppression decreased. This finding illustrates how costimulation signals serve dual roles in both effector T-cell activation and tolerance mechanisms.

The modulation of central memory T-cell trafficking may contribute to therapeutic effects. In type 1 diabetes, abatacept inhibited transmigration of central memory CD4+ T cells across endothelial cells, potentially affecting their migration and retention in lymphoid tissues where they encounter antigen. The reduction in this activated, antigen-experienced population accompanied by expansion of naive cells represented a shift toward less inflammatory immune states.

Study Quality and Limitations

Several factors affect interpretation of these findings across studies. Sample size limitations were notable, particularly for immunological endpoints. The GVHD first-in-disease trial included only 10 patients, and not all type 1 diabetes patients could be tested at each timepoint, potentially limiting detection of subtle subset changes. The multiple sclerosis trial enrolled 65 participants, which, while larger, still constrained generalizability. The smaller 7/8-HLA-mismatched GVHD stratum had only 43 recipients.

Technical considerations included high variance in absolute T-cell subset counts in type 1 diabetes studies and exclusion of samples with fewer than 50 events in multiple sclerosis flow cytometry analyses. These technical limitations could introduce bias or reduce precision. Most studies focused on peripheral blood samples, which might not fully represent T-cell responses in tissues or other compartments.

Confounding medications were common. Rheumatoid arthritis trials used methotrexate in combination with abatacept, GVHD prevention studies combined abatacept with cyclosporine and methotrexate, making it difficult to isolate abatacept-specific effects. The type 1 diabetes studies were validation studies conducted with only half of the eventual total subjects, indicating incomplete data at the time of publication.

Several studies acknowledged important gaps. Rheumatoid arthritis trials examined only patients with inadequate methotrexate response, not those with early disease. Type 1 diabetes investigators noted the need for more specific Treg markers and functional assessments to fully characterize tolerance effects. The asthma study’s patient population was limited to mild atopic asthma, potentially limiting generalizability to severe disease.

Synthesis

The evidence reveals a consistent pattern: abatacept reduces T-cell activation markers and shifts CD4+ compartments toward naive phenotypes while showing limited effects on CD8+ cells. However, the relationship between these immunological changes and clinical outcomes varies substantially across diseases, warranting careful examination of why similar T-cell effects produce different therapeutic results.

Context-Specific Clinical Translation

In GVHD prevention, the transient reduction in CD4+ T-cell activation and proliferation at day +28 aligned with favorable clinical outcomes, including low rates of severe GVHD (2.5% grade 3-4 in the 8/8-matched randomized cohort). The 7-10-fold reduction in proliferating and activated effector memory CD4+ T cells occurred during the critical early post-transplant window when donor T cells encounter recipient antigens, potentially explaining clinical benefit despite the transient nature of effects.

In contrast, the asthma study found increased naive and decreased memory CD4+ T cells but no significant reduction in allergen-induced eosinophilic inflammation or improvements in FEV1, methacholine responsiveness, or symptoms. This divergence between immunological and clinical effects suggests that CD28-dependent T-cell responses may not be the dominant driver of allergen-induced inflammation in mild atopic asthma, or that the 3-month treatment duration was insufficient for clinically meaningful effects in this chronic condition.

Subset-Specific Mechanisms

The differential kinetics and magnitude of effects across T-cell subsets explain some heterogeneity. In multiple sclerosis, Treg frequency changes occurred at 4 weeks while Tfh declines appeared at 16 weeks, suggesting that not all CD28-dependent processes have equivalent sensitivity to blockade. Memory Tregs (CD45RO+) decreased while naive Tregs (CD45RA+) remained constant, indicating that antigen-experienced regulatory populations are more dependent on ongoing costimulation than their naive counterparts. This mechanistic insight predicts that abatacept would have greater effects in settings dominated by memory T-cell responses compared to those requiring de novo T-cell priming.

The Treg Paradox

The apparently contradictory findings regarding regulatory T cells—increased numbers but decreased function in rheumatoid arthritis versus decreased frequencies in multiple sclerosis—can be reconciled by considering that CD80/CD86 serve dual roles. In rheumatoid arthritis, abatacept increased Treg numbers by reducing CD95-mediated apoptosis while simultaneously blocking CD80/CD86 on responder T cells, making them less susceptible to Treg suppression. This mechanism would maintain or increase Treg numbers while reducing their functional impact. In multiple sclerosis, the focus on memory Tregs that require costimulation for maintenance explains their selective depletion. Both findings may be correct within their respective contexts: rheumatoid arthritis involving high baseline inflammation and apoptosis versus multiple sclerosis where memory Treg maintenance is critical.

Disease Activity and Baseline State

Studies examining patients with active, established disease (rheumatoid arthritis with inadequate methotrexate response, active GVHD prevention) showed more robust clinical benefits from abatacept compared to those with mild disease activity (mild atopic asthma). This pattern suggests a dose-response relationship where higher baseline T-cell activation provides more opportunity for therapeutic benefit from costimulation blockade. The significant reductions in inflammatory biomarkers in rheumatoid arthritis patients (IL-6, soluble IL-2 receptor, CRP) reflected high baseline inflammation that responded to suppression of activated T cells.

Reversibility and Treatment Duration

The consistent reversibility of T-cell changes after treatment cessation indicates that abatacept does not induce permanent immune reprogramming or tolerance but maintains an altered immune state through continuous inhibition. This explains why type 1 diabetes studies required 24 months of continuous treatment to demonstrate slowed β-cell decline and why the transient 4-dose regimen in GVHD prevention was sufficient for that acute condition but might not sustain effects in chronic autoimmunity. The temporal alignment between drug exposure and immunological effects supports a pharmacological rather than tolerogenic mechanism.

Confounder Effects

The universal use of concomitant immunosuppression in clinical trials complicates attribution of effects solely to abatacept. Methotrexate, used in all rheumatoid arthritis studies, has independent effects on T-cell activation and proliferation. The combination of calcineurin inhibitors and methotrexate in GVHD prevention provides baseline immunosuppression that may interact synergistically with costimulation blockade. Studies showed that abatacept effects were most evident when the baseline regimen alone was insufficient, suggesting that costimulation blockade addresses a distinct mechanism not fully covered by other agents.

Clinical Implications by Context

For acute T-cell-mediated conditions like GVHD, the transient but profound reduction in CD4+ effector memory activation during the critical early post-transplant period appears sufficient for clinical benefit. For chronic autoimmune diseases like type 1 diabetes and rheumatoid arthritis, sustained treatment produces gradual shifts in T-cell compartments toward less activated states, translating to slowed disease progression over months to years. In diseases where CD28-independent pathways dominate, costimulation blockade alone may be insufficient regardless of its immunological effects.